东方财富证券给予心脉医疗增持评级动态点评：业绩稳健增长产品竞争力持续提升

每日经济新闻03-12

东方财富证券03月12日发布研报称，给予心脉医疗（688016.SH，最新价：187.55元）增持评级。评级理由主要包括：1）业务规模不断扩大，海外占比持续提升；2）研发实力强劲，在研管线进展顺利。风险提示：产品集中带量采购政策变化风险产品升级及新产品开发风险市场竞争加剧风险。AI点评：心脉医疗近一个月获得2份券商研报关注，买入2家。文章来源：每日经济新闻原标题：东方财富证券给予心脉医疗增持评级，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2418845715?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-12 17:33","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2418845715","market":"sh","top_or_hot":-1,"title":"东方财富证券给予心脉医疗增持评级 动态点评：业绩稳健增长 产品竞争力持续提升","media":"每日经济新闻","content":"<div>\n<p>东方财富证券03月12日发布研报称，给予心脉医疗（688016.SH，最新价：187.55元）增持评级。评级理由主要包括：1）业务规模不断扩大，海外占比持续提升；2）研发实力强劲，在研管线进展顺利。风险提示：产品集中带量采购政策变化风险产品升级及新产品开发风险市场竞争加剧风险。AI点评：心脉医疗近一个月获得2份券商研报关注，买入2家。文章来源：每日经济新闻原标题：东方财富证券给予心脉医疗增持评级，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031218192587766271&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>东方财富证券给予心脉医疗增持评级 动态点评：业绩稳健增长 产品竞争力持续提升</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n东方财富证券给予心脉医疗增持评级 动态点评：业绩稳健增长 产品竞争力持续提升\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-12 17:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031218192587766271&s=b><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>东方财富证券03月12日发布研报称，给予心脉医疗（688016.SH，最新价：187.55元）增持评级。评级理由主要包括：1）业务规模不断扩大，海外占比持续提升；2）研发实力强劲，在研管线进展顺利。风险提示：产品集中带量采购政策变化风险产品升级及新产品开发风险市场竞争加剧风险。AI点评：心脉医疗近一个月获得2份券商研报关注，买入2家。文章来源：每日经济新闻原标题：东方财富证券给予心脉医疗增持评级，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031218192587766271&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688016","symbol_name":"心脉医疗","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031218192587766271&s=b","article_id":"2418845715","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031218192587766271&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2418845715","pubTimestamp":1710236016,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"东方财富证券03月12日发布研报称，给予心脉医疗（688016.SH，最新价：187.55元）增持评级。评级理由主要包括：1）业务规模不断扩大，海外占比持续提升；2）研发实力强劲，在研管线进展顺利。风险提示：产品集中带量采购政策变化风险产品升级及新产品开发风险市场竞争加剧风险。AI点评：心脉医疗近一个月获得2份券商研报关注，买入2家。文章来源：每日经济新闻原标题：东方财富证券给予心脉医疗增持评级，动态点评：业绩稳健增长，产品竞争力持续提升","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"688016":"心脉医疗"},"translate_title":"Oriental Fortune Securities gave a dynamic comment on Xinmai Medical's overweight rating: Steady growth in performance and continuous improvement in product competitiveness","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688016":0.9},"content_text":"东方财富证券03月12日发布研报称，给予心脉医疗（688016.SH，最新价：187.55元）增持评级。评级理由主要包括：1）业务规模不断扩大，海外占比持续提升；2）研发实力强劲，在研管线进展顺利。风险提示：产品集中带量采购政策变化风险产品升级及新产品开发风险市场竞争加剧风险。AI点评：心脉医疗近一个月获得2份券商研报关注，买入2家。文章来源：每日经济新闻原标题：东方财富证券给予心脉医疗增持评级，动态点评：业绩稳健增长，产品竞争力持续提升","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2418845715"}

东方财富证券给予心脉医疗增持评级 动态点评：业绩稳健增长 产品竞争力持续提升

精彩评论

东方财富证券给予心脉医疗增持评级动态点评：业绩稳健增长产品竞争力持续提升